AstroNova, Inc. (ALOT) Reaches $18.00 After 6.00% Up Move; AIT THERAPEUTICS (AITB) Sellers Increased By 150% Their Shorts

April 16, 2018 - By David Stenberg

AstroNova, Inc. (NASDAQ:ALOT) Logo

The stock of AstroNova, Inc. (NASDAQ:ALOT) is a huge mover today! The stock increased 6.51% or $1.1 during the last trading session, reaching $18. About 58,468 shares traded or 113.61% up from the average. AstroNova, Inc. (NASDAQ:ALOT) has risen 4.32% since April 16, 2017 and is uptrending. It has underperformed by 7.23% the S&P500.The move comes after 6 months positive chart setup for the $122.39M company. It was reported on Apr, 16 by Barchart.com. We have $19.08 PT which if reached, will make NASDAQ:ALOT worth $7.34 million more.

AIT THERAPEUTICS INC (OTCMKTS:AITB) had an increase of 150% in short interest. AITB’s SI was 1,000 shares in April as released by FINRA. Its up 150% from 400 shares previously. With 3,000 avg volume, 0 days are for AIT THERAPEUTICS INC (OTCMKTS:AITB)’s short sellers to cover AITB’s short positions. The SI to AIT THERAPEUTICS INC’s float is 0.03%. The stock decreased 5.00% or $0.15 during the last trading session, reaching $2.85. About 600 shares traded. AIT Therapeutics, Inc. (OTCMKTS:AITB) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.

AIT Therapeutics, Inc., a biopharmaceutical company, engages in developing a single proprietary formulation of 160 parts per million of nitric oxide and delivery systems to treat respiratory infections. The company has market cap of $23.93 million. The companyÂ’s pipeline includes therapies against respiratory infections in acute and chronic diseases, such as severe bronchiolitis , cystic fibrosis related lung infections (CF), and non-tuberculosis mycobacterial (NTM) infections. It currently has negative earnings. It has completed two Phase II trials to treat RSV and CF related lung infections, as well as conducted a treatment for patients with CF who suffer from NTM infections.

Investors sentiment increased to 1.56 in Q4 2017. Its up 0.76, from 0.8 in 2017Q3. It improved, as 2 investors sold AstroNova, Inc. shares while 7 reduced holdings. 4 funds opened positions while 10 raised stakes. 3.71 million shares or 0.93% more from 3.68 million shares in 2017Q3 were reported. Morgan Stanley owns 3,750 shares or 0% of their US portfolio. Rutabaga Mngmt Ltd Liability Corp Ma invested in 0.83% or 259,070 shares. Wellington Management Grp Llp stated it has 0% of its portfolio in AstroNova, Inc. (NASDAQ:ALOT). Spark Mgmt Ltd Limited Liability Company reported 13,000 shares. Deutsche Bankshares Ag stated it has 10,387 shares or 0% of all its holdings. Kokino Ltd owns 21,745 shares. Blackrock owns 16,365 shares or 0% of their US portfolio. Shufro Rose Communications Ltd Company holds 0.01% or 10,879 shares. Royal Fincl Bank Of Canada invested in 2 shares or 0% of the stock. Punch & Assoc Inv holds 0.42% or 349,220 shares. 60,048 are owned by Granite Investment Partners Limited Liability Co. National Bank Of America Corporation De has 0% invested in AstroNova, Inc. (NASDAQ:ALOT). Salem Invest Counselors invested in 139,345 shares. 1,964 were reported by Panagora Asset Mngmt. The Pennsylvania-based Sei Investments Co has invested 0% in AstroNova, Inc. (NASDAQ:ALOT).

AstroNova, Inc. designs, develops, manufactures, and distributes specialty printers, and data acquisition and analysis systems in the United States, Canada, and Western Europe. The company has market cap of $122.39 million. The firm operates in two divisions, Product Identification and Test & Measurement. It has a 38.3 P/E ratio. The Product Identification segment offers digital color label printers and specialty OEM printing systems; and consumables, such as labels, tags, inks, toner, and thermal transfer ribbons, as well as software used to design and print labels under the QuickLabel brand.

Since December 18, 2017, it had 0 insider purchases, and 1 sale for $70,290 activity. The insider PIZZUTI EVERETT V sold 5,000 shares worth $70,290.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 David Stenberg

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: